\n Sanofi
\n <\/a>
\n va prochainement arr\u00eater de commercialiser un traitement de l’hypothyro\u00efdie qui se caract\u00e9rise par une insuffisance de s\u00e9cr\u00e9tion d’hormones par la glande thyro\u00efde, a annonc\u00e9 jeudi l’agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament (ANSM).\n<\/p>\n\n Le groupe tricolore a inform\u00e9 l\u2019ANSM de \u00ab\u00a0l\u2019arr\u00eat de la commercialisation de Cynomel (liothyronine sodique)\u00a0\u00bb, un traitement qui concerne environ 3.000 patients, \u00ab\u00a0\u00e0 compter du 31 octobre 2025\u00a0\u00bb, selon un communiqu\u00e9 de l’agence sanitaire qui a pr\u00e9vu une solution de remplacement.\n<\/p>\n
\n Interrog\u00e9e sur les raisons de cet arr\u00eat de commercialisation, l’ANSM a r\u00e9pondu qu’il faisait suite \u00e0 \u00ab\u00a0un arr\u00eat de la production\u00a0\u00bb de Cynomel, commercialis\u00e9 uniquement en France.\n<\/p>\n
\n \u00ab\u00a0En 2022, l\u2019entreprise charg\u00e9e de la production du Cynomel pour Sanofi a annonc\u00e9 son intention de cesser cette activit\u00e9. Un stock de s\u00e9curit\u00e9 a \u00e9t\u00e9 produit afin d\u2019anticiper l\u2019arr\u00eat de production. Ce stock permettra d\u2019approvisionner le march\u00e9 fran\u00e7ais jusqu\u2019en octobre 2025\u00a0\u00bb, a pr\u00e9cis\u00e9 Sanofi \u00e0 l’AFP.\n<\/p>\n
\n \u00ab\u00a0Pour assurer la continuit\u00e9 de traitement des patients\u00a0\u00bb, le laboratoire s\u2019est engag\u00e9 \u00e0 importer en France un traitement alternatif, le Thybon 20 Henning (liothyronine chlorhydrate), autoris\u00e9 en Allemagne depuis plus de 25 ans, souligne l’ANSM.\n<\/p>\n
\n Selon le communiqu\u00e9, ces importations prendront effet d\u00e8s l\u2019arr\u00eat de commercialisation du Cynomel et seront suivies d\u2019une demande d\u2019autorisation de mise sur le march\u00e9 pour le Thybon, afin d'\u00a0\u00bbassurer un acc\u00e8s p\u00e9renne \u00e0 ce m\u00e9dicament\u00a0\u00bb et \u00ab\u00a0d\u2019\u00e9viter aux patients des changements r\u00e9p\u00e9t\u00e9s de m\u00e9dicament\u00a0\u00bb.\n<\/p>\n
\n \u00ab\u00a0Il n\u2019y aura ainsi pas de rupture d\u2019approvisionnement entre la fin de distribution de Cynomel et le d\u00e9but de mise \u00e0 disposition de Thybon\u00a0\u00bb, assure l’ANSM.\n<\/p>\n
\n Les deux m\u00e9dicaments ont la m\u00eame mol\u00e9cule de base (liothyronine) mais des excipients diff\u00e9rents.<\/p>\n","protected":false},"excerpt":{"rendered":"( AFP \/ LOU BENOIST ) Le g\u00e9ant pharmaceutique Sanofi va prochainement arr\u00eater de commercialiser un traitement de…\n","protected":false},"author":2,"featured_media":102403,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[400,398,408,405,1011,27,72,403,402,399,404,71,401,406,407],"class_list":{"0":"post-255030","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-sante","8":"tag-action-cac-40","9":"tag-bourse-de-paris","10":"tag-boursorama","11":"tag-cotations","12":"tag-fr","13":"tag-france","14":"tag-health","15":"tag-indices-devises","16":"tag-investir","17":"tag-investissement","18":"tag-marche-boursier","19":"tag-sante","20":"tag-sicav","21":"tag-trackers","22":"tag-warrants"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@fr\/114871141935967103","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/posts\/255030","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/comments?post=255030"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/posts\/255030\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/media\/102403"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/media?parent=255030"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/categories?post=255030"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/tags?post=255030"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
![\"(](\"https:\/\/www.europesays.com\/fr\/wp-content\/uploads\/2025\/05\/2d058084c8dcdfece0df9a7f59ad379a-760x507.jpg\")
<\/p>\n